Media stories about Foamix Pharmaceuticals (NASDAQ:FOMX) have trended somewhat negative on Saturday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.0545589423547 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
FOMX has been the subject of a number of recent analyst reports. Credit Suisse Group reiterated a “buy” rating and set a $9.00 price target on shares of Foamix Pharmaceuticals in a research report on Wednesday, July 19th. HC Wainwright initiated coverage on shares of Foamix Pharmaceuticals in a research report on Thursday, August 24th. They set a “buy” rating and a $12.00 price target for the company. Finally, Zacks Investment Research cut shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd.
Shares of Foamix Pharmaceuticals (NASDAQ FOMX) opened at 6.04 on Friday. The firm’s market capitalization is $226.05 million. The firm’s 50 day moving average is $5.90 and its 200-day moving average is $5.01. Foamix Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $11.27.
Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.05). Foamix Pharmaceuticals had a negative net margin of 823.74% and a negative return on equity of 39.20%. The firm had revenue of $0.80 million during the quarter, compared to analyst estimates of $1.50 million. During the same period last year, the business earned ($0.27) EPS. The firm’s revenue was up 6.7% compared to the same quarter last year. On average, analysts expect that Foamix Pharmaceuticals will post ($1.53) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/28/foamix-pharmaceuticals-fomx-receiving-somewhat-critical-media-coverage-accern-reports.html.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.